To better understand SGD Pharma and their plans for the future, we at EPM HQ sat down with Olivier Rousseau, CEO of SGD Pharma, for a quick discussion.
Typically, Q&A’s are focused on a single topic or a single individual. To keep things interesting, here at EPM HQ, we devised a range of questions to put towards a varied group of subject matter experts at Lonza. Here’s what they had to say…
Campbell Bunce, Chief Scientific Officer and Cambridge Site Head at Abzena looks at how ADCs are being integrated with the capacity to modulate the immune system and how this marks a progressive shift in the fight against cancer.
Signal detection in post-market drug monitoring has changed little in 70 years, but now that shake-up is coming in the form of advanced AI technology combined with democratised access to standardised real-world data, Elizabeth Smalley explores.
In this article, Dr Julian Northen, Solid State Manager at Onyx Scientific, explores the challenges associated with achieving sustainability in pharma and the solutions the industry must adopt to ensure alignment with global goals and regulations.
Josh Ludwig, Global Commercial Director, ScaleReady explores the necessity of simplifying cell and gene therapy in order to successfully integrate artificial intelligence and automation technologies in our latest EPM insight.
Professor Afzal R Mohammed, Professor of Pharmaceutics at Aston University and advisor to Max Bio+, explores two promising advancements being explored that could revolutionise biological drug delivery: liquid-based delivery and inhalation.
Cornell Stamoran, Vice President, Strategy and Government Affairs, Catalent and Matt Mollan, Vice President Operations at Catalent explore the complexities of manufacturing orphan drugs in product development for our EPM Magazine.
Featured in our latest EPM Magazine Issue, Richard Hammond, Chief Technical Officer at Sphere Fluidics provides a vendor's perspective to introducing new equipment into GMP facilities.
